Replies to post #121061 on Biotech Values

[genisi]

UTHR/FREEDOM-M trial for oral Treprostinil

Tyvaso also showed improvement in placebo-adjusted median 6 minute walk distance of approximately 20 meters and missed its secondary endpoints in TRIUMPH study, but was approved.